The role of mode of action studies in extrapolating to human risks in toxicology

Toxicology Letters

Volumn 140-141, Issue , 2003, Pages 317-322

  Lock, Edward A ^a   Smith, Lewis L ^a  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Liver cancer; Mode of action; NTBC; Ocular toxicity; Risk assessment; Tamoxifen

Indexed keywords

2 (2 NITRO 4 TRIFLUOROMETHYLBENZOYL) 1,3 CYCLOHEXADIONE; CARCINOGEN; CYCLOHEXANE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; CANCER DIAGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HEALTH HAZARD; HUMAN; INGESTION; INHALATION; INJECTION; LIVER CANCER; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; TARGET ORGAN; TOXICOLOGY;

EID: 0037432649     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(03)00028-6     Document Type: Conference Paper

References (18)

1. Adam H.K., Patterson J.S., Kemp J.V. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat. Rep. 64:1980;761-764.
2. Aldridge W.N. Mechanisms of toxicity: new concepts are required in toxicology. Trends Pharamacol. 2:1981;228-231.
3. Aldridge W.N. The biological basis and measurement of thresholds. Ann. Rev. Pharmacol. Toxicol. 26:1986;39-58.
4. Ellis M.K., Whitfield A.C., Gowan L.A., Auton T., Provan W.M., Lock E.A., Smith L.L. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione and 2-(2-chloro-4-methanesulphonylbenzoyl)-1,3-cyclohexanedione. Toxicol. Appl. Pharmacol. 133:1995;12-19.
5. Fromson J.M., Pearson S., Bramah S. Metabolism of tamoxifen (ICI 46,474) I. In laboratory animals. Xenobiotica. 3:1973;711-714.
6. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistaer-derived rats. Cancer Res. 53:1993;3919-3924.
7. Goldsmith L.A. Tyrosinemia II: lessons in molecular pathophysiology. Pediatr. Dermatol. 1:1983;25-34.
8. Hall M.G., Wilks M.F., Provan W.M., Eksborg S., Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br. J. Clin. Pharmacol. 52:2001;169-177.
9. Holme E., Lindstedt S. Nontransplant treatment of tyrosinemia. Clin. Liver Dis. 4:2000;805-814.
10. IARC, 1996. Tamoxifen, in some pharmaceutical drugs, Lyon, France, pp. 253-365.
11. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., Strandvik B. Treatment of hereditary tyrosinaemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 340:1992;813-817.
12. Lock E.A., Gaskin P., Ellis M.K., Provan W.P., Robinson M., Smith L.L., Prisbylla M.P., Mutter L.C. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione(NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol. Appl. Pharmacol. 141:1996;439-447.
13. Lock E.A., Gaskin P., Ellis M.K., Provan W.P., Robinson M., Smith L.L. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC): effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology. 144:2000;179-187.
14. 32P-post labelling DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis. 16:1995;1651-1654.
15. Rich L.F., Beard M.E., Burns R.P. Excess dietary tyrosine and corneal lesions. Exp. Eye Res. 17:1973;87-97.
16. Smith L.L., Brown K., Carthew P., Lim C.-K., Martin E.A., Styles J., White I.H. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit. Rev. Toxicol. 30:2000;571-594.
17. Tucker M.J., Adams H.K., Patterson J. Laurence D.R., McLean A.E.M., Weatherall M. Tamoxifen, in Safety Testing of New Drugs. 1984;125-161 Academic Press, New York.
18. US Environmental Protection Agency, 1999. Draft guidelines for carcinogen risk assessment. Washington, DC, USA.